8-K: Xtant Medical Announces Major Stock Transaction and Preliminary Q1 2025 Revenue Growth

Xtant Medical reports a significant stock transaction involving OrbiMed and Nantahala Capital, alongside preliminary Q1 2025 revenue growth of 18% to 19%.

Summary

• Xtant Medical Holdings, Inc. announced the completion of a secondary private sale of 73.1 million shares from OrbiMed Advisors LLC to new and existing stockholders, led by Nantahala Capital Management LLC.
• The transaction resulted in OrbiMed no longer being a stockholder of the company.
• Nantahala now holds approximately 49.1% of the company's outstanding common stock.
• The company amended its credit agreements to increase the Change in Control threshold from 40% to 49.9%.
• Xtant terminated its Investor Rights Agreement with ROS Acquisition and ORO II.
• The company expects to report Q1 2025 revenue between $32.8 million and $33.1 million, representing 18% to 19% growth compared to Q1 2024.
• The company will file a shelf resale registration statement with the SEC within 30 days to register the resale of the shares.
• The company aims to have the resale registration statement declared effective within 60 days (or 90 days if reviewed by the SEC).

Sentiment

Score: 7

Explanation: The sentiment is moderately positive due to the revenue growth and new investment, but tempered by the risks associated with concentrated ownership and potential stock dilution.

Positives

• The company expects to report Q1 2025 revenue between $32.8 million and $33.1 million, representing 18% to 19% growth compared to Q1 2024.
• The termination of the Investor Rights Agreement with OrbiMed provides Xtant with greater strategic and operational flexibility.
• The company is shifting towards higher-margin orthobiologics and leveraging its Montana manufacturing facility to drive cost efficiencies.
• New product launches are planned to expand offerings beyond spine, which is expected to accelerate growth in 2025 and beyond.

Negatives

• Nantahala's significant ownership could allow them to exert substantial influence over the company's management and affairs, potentially conflicting with the interests of other stockholders.
• The sale of a substantial amount of common stock could adversely affect the market price of the common stock and impair the company's ability to raise capital through equity offerings in the future.
• The company is supplementing its risk factors due to Nantahala's significant ownership.

Risks

• Nantahala's significant ownership could lead to conflicts of interest and negatively impact the trading price of the common stock.
• Future sales of shares by Nantahala or other stockholders could adversely affect the market price of the common stock.
• The company's ability to comply with NYSE American listing standards following the loss of its controlled company status is uncertain.
• The company faces risks related to its ability to execute its strategic priorities, manage supply chain disruptions, and maintain sufficient liquidity.

Future Outlook

The company is focused on prioritizing profitability and achieving self-sustainability as the foundation of its long-term growth strategy, with a continued shift toward higher-margin orthobiologics and new product launches planned in the near term.

Management Comments

• 'We want to thank OrbiMed for its partnership and investment in Xtant over the years,' stated Sean Browne, President and CEO of Xtant Medical.
• Mr. Browne continued, 'We are pleased that this transaction has resulted in significant ownership by long-term, healthcare-focused investors who are aligned with our vision and fully committed to maximizing stockholder value.'
• 'We are pleased to partner with Xtant at such an exciting moment,' commented Dan Mack, Managing Member of Nantahala.
• Mr. Mack added, 'We fully support Xtants increased strategic focus on orthobiologics, which we believe will maximize stockholder value.'

Industry Context

The announcement highlights a shift towards orthobiologics, aligning with the increasing demand for regenerative and cost-effective surgical solutions in the healthcare space.

Comparison to Industry Standards

• The company's focus on orthobiologics aligns with the trend of companies like SeaSpine and Orthofix who are also investing in this high-growth area.
• The revenue growth of 18-19% is a positive sign, but it needs to be compared to the growth rates of its direct competitors to assess its relative performance.
• Companies like Globus Medical and NuVasive are key competitors in the spinal implant market, and their performance should be considered when evaluating Xtant's market position.

Stakeholder Impact

• Shareholders may experience volatility in the stock price due to the significant stock transaction and potential future sales.
• Employees may be affected by the strategic shift towards orthobiologics and the influence of the new major shareholder.
• Customers may benefit from the company's focus on innovative biologics and implant solutions.
• Suppliers may be impacted by the company's efforts to drive operational cost efficiencies.

Next Steps

• The company will file a shelf resale registration statement with the SEC within 30 days of the closing date.
• The company will seek to have the resale registration statement declared effective by the SEC within 60 days of the closing date (or 90 days if reviewed by the SEC).

Key Dates

Keywords

Xtant Medical, Nantahala Capital, OrbiMed, Stock Purchase Agreement, Revenue Growth, Orthobiologics, Change in Control, Registration Rights Agreement, Investor Rights Agreement, Share Sale